Betaxolol (CAS 63659-18-7) Suppliers and Product Information

Betaxolol is a cardioselective β1-adrenergic blocker used as an antihypertensive and antiglaucoma agent. It is a white crystalline solid with the IUPAC name 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]propan-2-ol. Betaxolol is used in the treatment of hypertension, arrhythmias, coronary heart disease, and glaucoma.

Frequently Asked Questions about Betaxolol

Q: What is the primary use of Betaxolol?

A: Betaxolol is primarily used as a cardioselective β1-adrenergic blocker for treating hypertension and glaucoma. It is also used in the management of arrhythmias and coronary heart disease.

Q: How does Betaxolol work in treating glaucoma?

A: Betaxolol reduces aqueous humor production by decreasing cyclic AMP synthesis in the ciliary body, which helps lower intraocular pressure in glaucoma patients.

Q: What are the advantages of Betaxolol over other beta-blockers?

A: Betaxolol is cardioselective, meaning it primarily targets β1 receptors. This selectivity makes it a potentially safer option for patients with concurrent respiratory diseases compared to non-selective beta-blockers.

Q: What is the typical dosing frequency for Betaxolol?

A: Due to its long plasma half-life of about 20 hours, Betaxolol is suitable for once-daily dosing in most cases.

Q: How is Betaxolol metabolized and eliminated from the body?

A: Betaxolol is primarily metabolized by the liver, with only about 15% of the unchanged drug being excreted. The absolute bioavailability of the drug is approximately 90%.